An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced the release date for its fourth quarter and full year 2021 financial results, scheduled for February 24, 2022, after market close. Following this, a conference call will take place at 4:30 p.m. ET to discuss the results and provide business updates. The call can be accessed via telephone or webcast. Details for call-in numbers and a link to the live webcast are available on the company's website. Sangamo focuses on developing genomic medicines for diseases lacking adequate treatment options.
Positive
Scheduled release of Q4 and full year 2021 financial results may provide insights into the company's financial health.
The upcoming conference call allows investors to gain direct updates from management.
Negative
None.
BRISBANE, Calif.--(BUSINESS WIRE)--
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its fourth quarter and full year 2021 financial results after the market closes on Thursday, February 24, 2022. The press release will be followed by a conference call at 4:30 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide business updates.
The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. The conference ID number for the call is 2235808. Participants may access the live webcast via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. A conference call replay will be available for one week following the conference call. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 2235808.
About Sangamo Therapeutics
Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently don’t exist. For more information about Sangamo, visit www.sangamo.com.
When will Sangamo Therapeutics release its Q4 and full year 2021 results?
Sangamo Therapeutics will release its Q4 and full year 2021 financial results on February 24, 2022.
What time is the Sangamo Therapeutics conference call scheduled?
The conference call for Sangamo Therapeutics is scheduled for 4:30 p.m. ET on February 24, 2022.
How can I access the Sangamo Therapeutics conference call?
The conference call can be accessed via telephone and webcast. Call-in numbers are (877) 377-7553 for domestic and (678) 894-3968 for international callers.
What is the conference ID for the Sangamo conference call?
The conference ID number for the Sangamo conference call is 2235808.
What does Sangamo Therapeutics focus on?
Sangamo Therapeutics focuses on developing genomic medicines using proprietary zinc finger genome engineering technology.
